Stored autologous blood transfusion does not increase recurrence of prostate cancer after radical prostatectomy: A preliminary study.
- Author:
Ying ZHANG
1
;
Xin-Sheng ZHANG
2
;
Shui-Ping ZHAO
2
;
Xin LI
2
;
Shi-Xiong LIU
2
;
Wan-Hong LI
3
Author Information
1. Department of Blood Transfusion,Taizhou Central Hospital, Taizhou, Zhejiang 318000, China.
2. Department of Urology, Taizhou Central Hospital, Taizhou, Zhejiang 318000, China.
3. Department of Blood Transfusion, Taizhou Central Hospital, Taizhou, Zhejiang 318000, China.
- Publication Type:Journal Article
- Keywords:
radical prostatectomy;
stored autologous blood transfusion;
tumor recurrence； metastasis;
prostate cancer
- From:
National Journal of Andrology
2019;25(5):430-433
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the association of stored autologous blood transfusion (SABT) with tumor recurrence in PCa patients after radical prostatectomy and explore the application of SABT in this surgical procedure.
METHODS:Forty-five PCa patients underwent radical prostatectomy in our hospital in recent five years, of whom, 20 received SABT (group A) and the other 25 allogeneic blood transfusion (group B) intraoperatively. After surgery, we followed up the patients regularly for 3－66 months by examination of the levels of total PSA (tPSA) and free PSA (fPSA), digital rectal examination (DRE), and MRI to observe the biochemical recurrence of the tumor. We compared the data obtained between the two groups of patients.
RESULTS:In group A, 8 cases were in stages T1a－T1b and 12 in stages T2a－T2c, and in group B, 14 cases were in stages T1a－T1b and 11 in stages T2a－T2c. The volume of transfused blood was 800 ml in group A and 400－1 200 ml in group B. No statistically significant differences were observed between the two groups in the operation time, intraoperative blood loss or postoperative Gleason scores (P > 0.05), nor in the tPSA level or the results of DRE and MRI at 12, 24, 36, 48 and over 48 months (P > 0.05).
CONCLUSIONS:SABT is safe for PCa patients undergoing radical prostatectomy and does not increase the tumor recurrence rate after surgery.
